Zydus Lifesciences Ltd News

New launches, India business growth key triggers for Zydus Lifesciences

Strong domestic growth, an expanding specialty portfolio, acquisitions and a robust product pipeline are expected to support Zydus Lifesciences' performance in FY27

Zydus Lifesciences up 2% to 52-wk high on USFDA review nod, buyback tweak

The pharmaceutical company said the buyback price has been increased from ₹1,150 per equity share to ₹1,260 per equity share

Zydus eyes Q4 FY27 US launch for liver disease drug after FDA review

The US FDA has granted priority review to Saroglitazar, Zydus Lifesciences' drug for treating Primary Biliary Cholangitis

Zydus Lifesciences shares gain 7%, hit 52-week high on healthy Q4 show

In the March quarter (Q4FY26), Zydus Lifesciences reported a net profit of ₹1,272.5 crore, as compared to ₹1,170.9 crore a year ago, up 8.7 per cent

Zydus Lifesciences Q4FY26 results: Profit up 9%, revenue jumps 16% in Q4

Zydus Lifesciences reported strong fourth-quarter earnings growth, supported by robust performance in India, international markets, and consumer wellness

Zydus Lifesciences jumps 5% as board to consider buyback, results on May 19

The buying on the counter came after the company, through a filing, said that its board will consider a buyback in a meeting along with the financial results on Tuesday, May 19, 2026

Zydus to acquire Assertio in ₹1,570 crore deal to expand US business

Acquisition gives Zydus a branded-drugs commercial platform in the US and strengthens its specialty pharmaceutical presence in pain and oncology therapies

Sun Pharma, Dr Reddy's Labs, Onesource: Nifty Pharma rallies 3%; details

Among others, Sun Pharma was the top gainer up over 7 per cent, followed by Gland Pharma, Alkem Laboratories, Zydus Lifesciences and Wockhardt up over 2 per cent

Pharma cos brace for soft Q4; US drag persists; domestic growth cushions

Pharma sector may see a 7 per cent Y-o-Y growth in reported sales and a 1 per cent increase in Ebitda, led by steady ex-gRevlimid US sales, healthy domestic growth, and favourable forex movements

10 pharma firms launch semaglutide in India; Nomura sees ₹12k-cr mkt

Companies including Dr. Reddy's Laboratories, Sun Pharma, Zydus Lifesciences, Natco Pharma, Alkem Laboratories, and Torrent Pharmaceuticals have developed their own formulations

Zydus, Lupin sign deal to co-market Semaglutide injections in India

Semaglutide is a GLP-1 receptor agonist used to treat Type 2 Diabetes and, increasingly, for weight management by helping regulate blood sugar and appetite

Stocks to Watch today, March 17: RIL, Tata Motors, Sun Pharma, RVNL, GMDC

Stocks to Watch today, March 17: Reliance Industries, Tata Motors, Sun Pharma, RVNL, GMDC, RailTel, and Sagar Cements are among the top stocks to watch today

Zydus drug Desidustat for renal anaemia gets regulatory nod in China

Zydus Lifesciences on Saturday said its innovative drug has received approval from China's National Medical Products Administration (NMPA) for its drug Desidustat tablets used for treating renal anaemia. The company has licensed its Desidustat tablets to a subsidiary of China Medical System Holdings Ltd. CMS International Development and Management Ltd, a wholly-owned subsidiary of CMS, had obtained an exclusive license for the drug from Zydus in 2020. Desidustat tablets are administered orally for treating anaemia in Chronic Kidney Disease (CKD) patients. CKD involves the gradual loss of kidney function and eventually leads to kidney failure. "We are encouraged by the NMPA's approval for marketing the drug in China. Our life-changing discoveries are driven by a commitment to improving patient outcomes and enabling healthier, more fulfilled lives, globally," Zydus Lifesciences MD Sharvil P Patel said in a statement. The company is happy to partner with CMS and is confident that th

Stocks to Watch today, Feb 26: Lupin, IRFC, RVNL, SBI Life, Sanofi India

Stocks to Watch today, February 26, 2026: IRFC, RVNL, Sanofi India are among shares that will be eyed by investors today

Stocks to Watch today, Feb 19: Dr Reddy's Labs, HUL, Cochin Shipyard, DLF

Stocks to Watch today, February 19, 2025: Dr Reddy's Labs, Hindustan Unilever, NCC, DLF, and Jindal Saw are some of the key stocks to watch today

Zydus agrees to pay $120 million to settle US patent dispute with Astellas

The deal will enable the company to continue marketing its generic Mirabegron in the United States, Zydus said, adding that other terms and conditions ​of the agreement are confidential

Zydus Lifesciences Q3 net profit rises 9% on strong US and India growth

Zydus Lifesciences posted higher Q3 profit and revenue, aided by strong growth in the US and India businesses, improved margins, and steady momentum in generics, specialty and chronic segments

Zydus Life Q3 result: Profit up marginally at ₹1,042 cr, revenue jumps 32%

Zydus Life Q3 Ebitda for the quarter was ₹1,816.4 crore, up 31 per cent Y-o-Y. Ebitda margin during the same period stood at 26.5 per cent, marking an improvement of 20 basis points

Q3 results: Pfizer, Zydus Lifesciences, Aurobindo Pharma, 181 more on Feb 9

Q3FY26 company results: Firms including GlaxoSmithKline Pharmaceuticals, The Ramco Cements, Linde India, Gulf Oil Lubricants, and Bata India are also to release their October-December earnings today

Zydus receives orphan drug status for Sickle Cell Disease medication

Zydus Lifesciences on Friday said the US health regulator has granted Orphan Drug Designation to Desidustat, a novel oral product medication for the treatment of Sickle Cell Disease. The US Food and Drugs Administration's (USFDA) grants orphan status to support development of medicines for the treatment of rare diseases that affect fewer than 2 lakh people in the US. "This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop a therapy for sickle cell disease. We believe that Desidustat can address this unmet need," Zydus Lifesciences MD Sharvil Patel said in a statement. Therapeutic options for management of Sickle Cell Disease are currently limited. A Phase II, double blind, randomised, placebo controlled, parallel, multi-centre, proof-of-concept study to evaluate the efficacy and safety of Desidustat oral tablet for treatment of SCD has been completed, and data will be published in a medical journal, the drug firm said. Orphan drug designation by